e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Systemic and airway biomarkers in respiratory diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Clara cells protein 16 (CC-16) level correlates with hemoglobin level in COPD patients
A. Nowinski, D. Korzybski, B. Bialas-Chromiec, D. Gorecka (Warsaw, Poland)
Source:
Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Session:
Systemic and airway biomarkers in respiratory diseases
Session type:
Thematic Poster Session
Number:
837
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Nowinski, D. Korzybski, B. Bialas-Chromiec, D. Gorecka (Warsaw, Poland). Clara cells protein 16 (CC-16) level correlates with hemoglobin level in COPD patients. Eur Respir J 2013; 42: Suppl. 57, 837
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Plasma surfactant protein D (SP-D) and comorbidity rate in patients with COPD
Source: International Congress 2014 – Predictors
Year: 2014
Inflammatory markers (IL-6, suPAR) and arterial stiffness parameters in COPD patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Serum BNP levels in COPD, asthma-COPD-overlap-syndrome, smokers and never-smokers
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
Plasma surfactant protein D (SP-D) in patients (pts) with stable (S) COPD and during COPD acute exacerbation (AE)
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013
Association of angiopoietin-like protein 4 with cardiovascular function in patients with COPD
Source: International Congress 2016 – Recent high impact findings regarding COPD comorbidities
Year: 2016
Plasma levels of TIPM-2 in patients with COPD
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts)
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Principles of optimization of anti-inflammatory therapy in COPD patients (pts) due to C-reactive protein (CRP) level
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013
The difference between surfactant protein D (SPD) and C-reactive protein (CRP) levels in patients (pts) with chronic obstructive pulmonary disease acute exacerbations (AE COPD) and community acquired pneumonia (CAP)
Source: International Congress 2014 – Clinical presentations
Year: 2014
Plasma surfactant protein D (SP-D) and smoking status in patients with COPD
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Serum sirtuin-1 is reduced in COPD
Source: International Congress 2016 – Systemic biomarkers
Year: 2016
COPD: Plasma surfactant protein-D (SPD) concentration as a predictor of acute exacerbations (AE) probability
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Alterations of the soluble proteome of airway epithelial cells in COPD
Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome)
Year: 2013
Serum vitamin D3 level correlates with FEV1 in patients with advanced COPD
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept